Cargando…

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy

BACKGROUND: There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear. METHODS: Stage II and III colorectal cancer patients who underwent curativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, D-W, Han, S-W, Lee, H J, Rhee, Y-Y, Bae, J M, Cho, N-Y, Lee, K-H, Kim, T-Y, Oh, D-Y, Im, S-A, Bang, Y-J, Jeong, S-Y, Park, K J, Park, J-G, Kang, G H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670503/ https://www.ncbi.nlm.nih.gov/pubmed/23652310 http://dx.doi.org/10.1038/bjc.2013.232

Ejemplares similares

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
por: Han, S-W, et al.
Publicado: (2009)

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
por: Yun, J, et al.
Publicado: (2011)

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
por: Kang, Y-K, et al.
Publicado: (2013)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
por: Kim, J-S, et al.
Publicado: (2009)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
por: Kim, D-W, et al.
Publicado: (2008)

Mucin 1-mediated chemo-resistance in lung cancer cells
por: Ham, S Y, et al.
Publicado: (2016)

Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
por: Lu, C-Y, et al.
Publicado: (2013)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Myelomatous effusion with poor response to chemotherapy.
por: Kim, Y. M., et al.
Publicado: (2000)

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
por: Yoo, C, et al.
Publicado: (2009)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Thoracic aortic aneurysm associated with aortitis--case reports and histological review.
por: Seo, J. W., et al.
Publicado: (1991)

The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C.
por: Lee, Y. S., et al.
Publicado: (2001)

Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives
por: Kim, J W, et al.
Publicado: (2008)

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
por: Park, S., et al.
Publicado: (2022)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
por: Cho, E.H., et al.
Publicado: (2021)

Ovarian mucinous cystadenoma with mural nodule of anaplastic carcinoma.
por: Hong, S. R., et al.
Publicado: (1998)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Vibrio vulnificus VvpE inhibits mucin 2 expression by hypermethylation via lipid raft-mediated ROS signaling in intestinal epithelial cells
por: Lee, S-J, et al.
Publicado: (2015)

Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2002)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

Histological and immunohistochemical studies on primary gastrointestinal lymphomas.
por: Lee, J. D., et al.
Publicado: (1993)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

Cytologic and histologic correlation of atypical glandular cells of undetermined significance.
por: Ha, S. Y., et al.
Publicado: (2001)

Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter study.
por: Bang, D, et al.
Publicado: (2001)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

Two cases of common bile duct stone after liver transplantation.
por: Byun, B. H., et al.
Publicado: (1999)

BRAF mutations in non-Hodgkin's lymphoma
por: Lee, J W, et al.
Publicado: (2003)

Surveillance of the Middle East respiratory syndrome (MERS) coronavirus (CoV) infection in healthcare workers after contact with confirmed MERS patients: incidence and risk factors of MERS-CoV seropositivity
por: Kim, C.-J., et al.
Publicado: (2016)

Hepatocellular carcinoma associated hemolytic uremic syndrome unrelated to chemotherapy.
por: Seo, D. W., et al.
Publicado: (1994)

Change in activity of the sympathetic nervous system in diet-induced obese rats.
por: Park, S. Y., et al.
Publicado: (2000)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_8l5sub4i8giqmdnvj2m0lks7ug